Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,536 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,903 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06636123 | GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy | recruiting | Phase 1 | 30 | Virginia Commonwealth UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07370597 | LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.(LUDOPATH) | recruiting | — | 110 | Jules Bordet InstituteOTHER | 1 | Jan 27, 2026 |
| clinicaltrials |
| NCT04402151 | Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer(PSMA SBRT-SIB) | recruiting | Phase 2 | 50 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07365397 | Imaging Characteristics of Different ⁶⁸Ga-PSMA Probes in Prostate Cancer | not yet recruiting | N/A | 9 | Shanghai Zhongshan HospitalOTHER | 0 | Jan 26, 2026 | clinicaltrials |
| NCT06811454 | Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET) | not yet recruiting | N/A | 76 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07363382 | The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer | recruiting | Phase 1 / Phase 2 | 6 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07363486 | Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 9 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05761912 | Application of Ultrasound Radiomics in Ultrasound Fusion Targeted Prostate Biopsy | active not recruiting | — | 464 | Shanghai Minhang Central HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07358806 | Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 51 | Oscotec Inc.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05327452 | Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study | active not recruiting | N/A | 135 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07291414 | A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients | recruiting | N/A | 80 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07343349 | Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions(DAPROCA10) | recruiting | N/A | 1,016 | Rigshospitalet, DenmarkOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07355504 | Prostate Cancer Early Detection Using Serial MRI Examinations(PROCEDE) | not yet recruiting | N/A | 380 | University Hospital, GrenobleOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT02914873 | SPCG17: Prostate Cancer Active Surveillance Trigger Trial(PCASTT) | active not recruiting | N/A | 2,008 | Uppsala UniversityOTHER | 5 | Jan 20, 2026 | clinicaltrials |
| NCT03937843 | Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma | active not recruiting | Phase 2 | 135 | Swiss Cancer InstituteOTHER | 2 | Jan 20, 2026 | clinicaltrials |
| NCT05301114 | Social Risk Factors and Discrimination in Cancer Survivorship | active not recruiting | N/A | 1,116 | Medstar Health Research InstituteOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05366881 | cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease(CAMPERR) | recruiting | — | 7,000 | Adela, IncINDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07351461 | Anxiety in Patients Under Active Surveillance for Localized Prostate Cancer and Their Partners.(ANCAPRO) | recruiting | — | 432 | University Hospital, LilleOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05038332 | Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT]) | recruiting | Phase 2 | 136 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05264337 | Lymphedema After Urologic Surgery | recruiting | — | 400 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06406803 | The Impact of Physical Activity Versus Dietary Energy Restriction on Tumour and Muscle Protein Synthesis in Prostate Cancer Patients(DIRECT) | recruiting | N/A | 45 | Maastricht University Medical CenterOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT03367702 | Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer | active not recruiting | Phase 3 | 692 | NRG OncologyOTHER | 6 | Jan 15, 2026 | clinicaltrials |
| NCT05745844 | Evaluation of Neuromuscular ElectroStimulation in Addition to a Physical Activity Program(HORMES) | recruiting | N/A | 48 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05838716 | Vitamin D for Prostate Endocrine Therapy(ViPER) | recruiting | Phase 3 | 240 | University of RochesterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06830850 | A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 1 | 25 | Atridia Pty Ltd.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07318051 | Sample Collection for Ongoing Research and Product Evaluation Study(SCORE) | recruiting | — | 9,600 | Natera, Inc.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07344844 | Adaptive Stereotactic Radiotherapy for Localized Prostate Cancer(SPAR) | recruiting | N/A | 100 | Clinique Sainte ClotildeOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05924672 | Efficacy of Ra-223 in PSMA PET Optimally Selected Patients | active not recruiting | Phase 2 | 2 | University of California, San FranciscoOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06059118 | Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT02229916 | Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS(SAG TCCS) | recruiting | — | 6,900 | Dr. med. Christian RothermundtOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04647526 | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment(SPLASH) | active not recruiting | Phase 3 | 455 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyINDUSTRY | 6 | Jan 13, 2026 | clinicaltrials |
| NCT05926102 | The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)(ProGRESS) | recruiting | N/A | 5,000 | VA Office of Research and DevelopmentFED | 1 | Jan 13, 2026 | clinicaltrials |
| NCT02454543 | Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases(g-RAMPP) | active not recruiting | N/A | 452 | Martini-Klinik am UKE GmbHOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04269512 | Role of Lymphnode Dissection in Men With Prostate Cancer Treated With Radical Prostatectomy(PREDICT) | active not recruiting | N/A | 3,650 | Martini-Klinik am UKE GmbHOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04271579 | Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)(ProsTone) | recruiting | N/A | 397 | Martini-Klinik am UKE GmbHOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06117059 | The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance(PRECISION) | recruiting | N/A | 100 | NHS LothianOTHER_GOV | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06353321 | Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1 | recruiting | — | 25 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07112612 | Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer | not yet recruiting | — | 50 | Anhui Medical UniversityOTHER | 0 | Jan 12, 2026 | clinicaltrials |
| NCT07129551 | Navigation, Outcomes and Quality-of-life in Prostate Cancer Patients Undergoing PSMA-targeted Surgery(NICE-PSMA) | recruiting | N/A | 102 | Martini-Klinik am UKE GmbHOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07181473 | A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 200 | Phrontline BiopharmaINDUSTRY | 2 | Jan 12, 2026 | clinicaltrials |
| NCT07334275 | Detection of Minimal Residual Disease Post-prostatectomy(MiRaDE) | recruiting | — | 50 | Radboud University Medical CenterOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04777071 | An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer | active not recruiting | Phase 2 | 141 | University of WashingtonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07112599 | Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis | recruiting | — | 2,000 | Anhui Medical UniversityOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05570994 | 177Lu-HTK03170 in mCRPC With PSMA Positive Disease | enrolling by invitation | Phase 1 / Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06660862 | Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer. | not yet recruiting | Phase 4 | 80 | University of ChicagoOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07282808 | Focal or Radical Therapy: a Lesion-based Molecular Evaluation in Prostate Cancer(FLAME-PC) | recruiting | N/A | 130 | Singapore General HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT00579163 | Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers | active not recruiting | — | 992 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jan 27, 2026source: clinicaltrials